Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis
inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis
function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help
smokers abstain from smoking during a 12-week trial period.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Rose Research Center, LLC
Collaborators:
Embera NeuroTherapeutics, Inc. Foundation for a Smoke-Free World